<DOC>
	<DOCNO>NCT00000663</DOCNO>
	<brief_summary>To determine safety profile , assess pharmacokinetic property ( blood level ) , obtain preliminary indication antiviral immunologic effect recombinant CD4 immunoglobulin G ( CD4-IgG ) . CD4-IgG may effective block HIV transmission spread , , CD4-IgG antiviral effect . Studies do adult patient AIDS AIDS relate complex ( ARC ) show rCD4 safely administer intravenous bolus , intramuscular subcutaneous injection . No serious dose-limiting , drug-related toxicity observe date .</brief_summary>
	<brief_title>A Phase I Study Safety Pharmacokinetics Recombinant CD4 Immunoglobulin G ( rCD4-IgG ) Infants Children With Documented HIV-1 Infection</brief_title>
	<detailed_description>CD4-IgG may effective block HIV transmission spread , , CD4-IgG antiviral effect . Studies do adult patient AIDS AIDS relate complex ( ARC ) show rCD4 safely administer intravenous bolus , intramuscular subcutaneous injection . No serious dose-limiting , drug-related toxicity observe date . Patients receive one intravenous injection first week , follow 6 day washout period intravenous injection twice weekly basis week 2 week 12 . The dose per injection may vary . The study evaluate 2 group : ( 1 ) Children 3 month 5 year age ; ( 2 ) Infants 0-3 month age .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>CD4 Immunoadhesins</mesh_term>
	<mesh_term>Immunoglobulin G</mesh_term>
	<criteria>Inclusion Criteria Patients must follow : HIV1 infection , less 15 month old , born mother HIV1 infection . Legally qualified guardian ability sign write , informed consent form . Willingness abstain experimental therapy HIV1 infection first 12 week study period . Anticipated life expectancy least 3 month . Prior Medication : Allowed : Prophylactic antiPneumocystis carinii pneumonia ( PCP ) antifungal therapy . Gamma globulin prophylaxis measles varicella . Exclusion Criteria Coexisting Condition : Patients follow condition symptom exclude : Past present history neurological abnormality include withdrawal syndrome seizure . Past present history serious active opportunistic infection include Pneumocystis carinii pneumonia ( PCP ) . Echocardiogram value &gt; 2 standard deviation normal . Hematologic , renal , hepatic insufficiency . Concurrent Medication : Excluded : Zidovudine ( AZT ) . Intravenous gamma globulin ( IVIG ) except prophylaxis measles varicella . Cancer chemotherapy . Corticosteroids . Other known immunomodulatory agent . Other experimental therapy specifically allow . Patients follow exclude : Hematologic , renal , hepatic insufficiency . Past present history serious active opportunistic infection . Prior Medication : Excluded minimum 3 week prior study entry : Zidovudine ( AZT ) . Intravenous gamma globulin ( IVIG ) . Cancer chemotherapy . Immunomodulatory agent . Acyclovir experimental therapy . Risk Behavior : Excluded : Patients bear substance abuse mother ( include alcohol ) pregnancy .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>5 Years</maximum_age>
	<verification_date>October 1996</verification_date>
	<keyword>Recombinant Proteins</keyword>
	<keyword>Injections , Intravenous</keyword>
	<keyword>IgG</keyword>
	<keyword>Drug Evaluation</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>Antigens , CD4</keyword>
	<keyword>Carrier Proteins</keyword>
</DOC>